JP7818504B2 - パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用 - Google Patents

パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用

Info

Publication number
JP7818504B2
JP7818504B2 JP2022513855A JP2022513855A JP7818504B2 JP 7818504 B2 JP7818504 B2 JP 7818504B2 JP 2022513855 A JP2022513855 A JP 2022513855A JP 2022513855 A JP2022513855 A JP 2022513855A JP 7818504 B2 JP7818504 B2 JP 7818504B2
Authority
JP
Japan
Prior art keywords
nanostructure
polypeptide
protein
assembly
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022513855A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021046207A5 (https=
JP2022546813A (ja
JP2022546813A5 (https=
Inventor
ニール ピー． キング
ブルック フィアラ
ジョージ ウエダ
ジョルジェ ハラス
Original Assignee
ユニヴァーシティ オブ ワシントン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティ オブ ワシントン filed Critical ユニヴァーシティ オブ ワシントン
Publication of JP2022546813A publication Critical patent/JP2022546813A/ja
Publication of JPWO2021046207A5 publication Critical patent/JPWO2021046207A5/ja
Publication of JP2022546813A5 publication Critical patent/JP2022546813A5/ja
Priority to JP2025142204A priority Critical patent/JP2025172875A/ja
Application granted granted Critical
Publication of JP7818504B2 publication Critical patent/JP7818504B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022513855A 2019-09-04 2020-09-03 パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用 Active JP7818504B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025142204A JP2025172875A (ja) 2019-09-04 2025-08-28 パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962895727P 2019-09-04 2019-09-04
US62/895,727 2019-09-04
PCT/US2020/049183 WO2021046207A1 (en) 2019-09-04 2020-09-03 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025142204A Division JP2025172875A (ja) 2019-09-04 2025-08-28 パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用

Publications (4)

Publication Number Publication Date
JP2022546813A JP2022546813A (ja) 2022-11-09
JPWO2021046207A5 JPWO2021046207A5 (https=) 2023-09-07
JP2022546813A5 JP2022546813A5 (https=) 2023-09-07
JP7818504B2 true JP7818504B2 (ja) 2026-02-20

Family

ID=72521748

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513855A Active JP7818504B2 (ja) 2019-09-04 2020-09-03 パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用
JP2025142204A Pending JP2025172875A (ja) 2019-09-04 2025-08-28 パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025142204A Pending JP2025172875A (ja) 2019-09-04 2025-08-28 パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用

Country Status (5)

Country Link
US (1) US20220306697A1 (https=)
EP (1) EP4025587A1 (https=)
JP (2) JP7818504B2 (https=)
CN (1) CN114502572A (https=)
WO (1) WO2021046207A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133435A2 (en) * 2022-01-07 2023-07-13 University Of Washington Novel immunogens for influenza virus vaccines
AU2023273041A1 (en) * 2022-05-17 2024-12-05 Icosavax, Inc. Multivalent vaccine for paramyxoviruses and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180137234A1 (en) 2016-11-16 2018-05-17 University Of Washington Computational Design of Self-Assembling Cyclic Protein Homo-oligomers
WO2018187325A1 (en) 2017-04-04 2018-10-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2707385T3 (da) 2011-05-13 2017-11-20 Glaxosmithkline Biologicals Sa RSV-F-præfusionsantigener
EA201590683A1 (ru) 2012-11-20 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. Тримеры rsv f, предшествующие слиянию
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
FI2970398T3 (fi) 2013-03-13 2024-08-06 Us Health Rsv f -prefuusioproteiineja ja niiden käyttö
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
JP6469081B2 (ja) 2013-04-25 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖｆポリペプチド
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
US20150166610A1 (en) 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
CA2996762A1 (en) 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
EP3393512B1 (en) 2015-12-23 2025-11-19 Pfizer Inc. Rsv f protein mutants
US11174292B2 (en) 2016-03-29 2021-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180137234A1 (en) 2016-11-16 2018-05-17 University Of Washington Computational Design of Self-Assembling Cyclic Protein Homo-oligomers
WO2018187325A1 (en) 2017-04-04 2018-10-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Also Published As

Publication number Publication date
EP4025587A1 (en) 2022-07-13
JP2022546813A (ja) 2022-11-09
US20220306697A1 (en) 2022-09-29
JP2025172875A (ja) 2025-11-26
WO2021046207A1 (en) 2021-03-11
CN114502572A (zh) 2022-05-13

Similar Documents

Publication Publication Date Title
US12275757B2 (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use
TWI756828B (zh) Rsv f蛋白突變體
JP2025172875A (ja) パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用
CN117202928A (zh) 用于偏肺病毒的基于蛋白质的纳米颗粒疫苗
US20250222092A1 (en) Protein nanostructure vaccine
RU2844177C2 (ru) Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение
HK40128177A (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
KR20250094574A (ko) 변이 rsv 단백질
KR20260010717A (ko) 코로나바이러스 스파이크 당단백질 수용체 결합 도메인 및 이의 용도
WO2025026448A1 (zh) 修饰的呼吸道合胞病毒f蛋白及其用途
HK40014567A (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
HK40014567B (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251015

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260209

R150 Certificate of patent or registration of utility model

Ref document number: 7818504

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150